Provider review
RxSpan MD review: it names its doctor, and never says what a price buys
RxSpan MD does something most of this market avoids: it names the doctor behind the service, with a full biography and a credential you can check. Then it publishes a price list with no billing period on it. Semaglutide is $249 — for what? A month, a quarter, one vial? The page does not say, there are no product pages to click through to, and no wording anywhere near those figures gives a term. You would have to start the signup to find out what you are being asked to pay for.
Partner link — we may earn a commission. How we’re paid
Visit RxSpan MDOf RxSpan MD’s 3 dated product claims documented below, 3 are consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $249 for 30 days (Compounded semaglutide injection, as listed). A matching claim does not mean the compounded product was tested or FDA-approved.
Names its physician and his credentials, then lists every price with no billing period attached to any of them.
Worth trusting if
- You want the doctor behind the service named, with a biography you can check
- You want a seller that makes no promise about how much weight you will lose
- You want the branded products listed beside the compounded ones at their real prices
Be skeptical if
- You need to know whether a price is a month, a quarter or a single vial before you start
- You want to know which pharmacy fills the prescription
- You want a physician whose board specialty is metabolic or internal medicine
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Approved + compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at RxSpan MD
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Wegovy, brand — Listed at $1,349 against $249 for the compounded version.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — Listed at $249 with no billing period stated anywhere on the page.
- Compounded tirzepatide injection — Listed at $329 for the injection and $349 for capsules, both without a term.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
3
Products with human evidence
For the advertised use, out of 3 products reviewed here. The evidence concerns the molecule, not RxSpan MD's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from RxSpan MD’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“Semaglutide Injection $249. […] Get started today with physician-guided weight loss solutions.”
Read on the RxSpan MD site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg, mean weight reduction of about 15%. Listed as the molecule's evidence base; RxSpan MD cites no trial anywhere on its site.
There is no outcome claim here to weigh against the trial. RxSpan MD sells on the credential of its physician and on convenience, and attaches no weight-loss percentage, pounds figure or timeline to this product anywhere. What is missing instead is the commercial information a buyer needs: the figure beside the product has no billing period attached, no product page exists to explain it, and the only qualifier in sight is a site-wide coupon. Saying nothing about efficacy is the right instinct; saying nothing about what that figure buys is not the same kind of restraint.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Tirzepatide Injection $329. […] Tirzepatide Capsules $349.”
Read on the RxSpan MD site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, mean reduction of roughly 21% at the top dose. Again the molecule's evidence base rather than a citation this seller makes.
The same pattern: a product name, a bare figure and no promise. Worth noting that RxSpan MD prices tirzepatide capsules above the injection, which is the usual direction in this market because an oral formulation generally needs far more drug to reach a comparable exposure — but no trial cited anywhere on this site, or on any site we grade, tested a compounded tirzepatide capsule. Nothing here overstates the evidence, and nothing here connects the product to it either.2
Wegovy, brandSemaglutide · FDA-approvedClaim matches the trials
“Wegovy® $1349. Zepbound® $1069. Ozempic® $1299.”
Read on the RxSpan MD site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. The trial supporting approval of this exact product. Unlike the compounded rows, the evidence here attaches to the thing being sold.
The branded products are the one place on this site where the trial evidence attaches directly to what is being sold, and RxSpan MD claims nothing for them beyond listing them. The gap between $1,349 for branded semaglutide and $249 for the compounded version is the trade a buyer is actually being offered, and the site does not frame it either way. Ozempic sits in the same list at $1,299, which is a diabetes medicine rather than a weight-management one — worth knowing before comparing the two figures.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. The terms say only that medications may be fulfilled by licensed pharmacies if prescribed, and nothing states whether your medication would be made to order under your prescription or dispensed ready-made. What RxSpan MD does name, unusually, is its physician — Dr. John Diaz, with a biography covering his degree, his medical school and his honors. That credential is real and checkable, and it is worth reading precisely: the board certification named is in plastic surgery rather than in endocrinology or internal medicine. That is not a disqualification, and plenty of physicians practice weight management outside their board specialty. It is simply the fact, and a site that leads with a doctor's credentials invites a reader to look at them.
Read on the RxSpan MD site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published — and neither is a billing period or a product page. The price list is a single index of bare figures, and its product links lead to pages that do not exist. The only strong claim on the whole property sits on a line this page does not grade: the hair-loss category promises clinically proven topicals and orals to slow loss and support regrowth, with no study named. Its weight-loss and peptide lines make no efficacy claim at all, which is the right instinct and leaves nothing to verify in either direction.
Read on the RxSpan MD site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
RxSpan MD publishes no list of states and makes no nationwide claim, on its homepage, products page, about page or terms. Its terms require that you be in the same state as your shipping address at the time of a consultation, which describes how telehealth works rather than where this company operates.
Read the full licensing claim
The operating company is named in its terms as RxSpan MD LLC, and a named physician is presented with a full biography on the about page. No pharmacy is named, and no address or state of incorporation appears.
Read on the RxSpan MD site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- It names its physician and publishes his degree, medical school and honors.
- It names its operating company in its own terms.
- It makes no weight-loss claim of any kind on its GLP-1 or peptide products.
Show 3 more
- It lists the branded products beside the compounded ones, so the price gap is visible.
- It publishes prices at all, before any signup, which several sellers we grade do not.
- No FDA warning letter, against the brand or the named physician.
- Not one price on the site carries a billing period — no month, supply, term or per-anything.
- There are no product pages; every product URL we tried returned a not-found page.
- The physician it names is board-certified in plastic surgery rather than metabolic medicine.
Show 4 more
- No pharmacy is named, and nothing says whether the medication is made to order.
- A 10% site-wide coupon means the first charge differs from every figure listed.
- Its hair-loss line claims clinically proven treatments and names no study.
- It sells NAD+, sermorelin and glutathione with no product page, dose or trial reference.
Verdict
The bottom line
Before anything else, ask what $249 buys — a month, a quarter, or one vial. Nothing on this site answers that, and it is the first thing you need. The physician is named and his credentials are real, which is more than most of this market offers; just read them carefully, because the board that certified him certified him in plastic surgery.
Opens RxSpan MD's website. A link is not a recommendation to take anything.
What support does the program include?
The October 13 homepage advertises physician review, appointments and messaging, and free expedited delivery. Those services make follow-up part of the offer, but they do not specify how quickly a clinician responds to an urgent medication question or how a refill is authorized. 3
Ask for the actual product, amount dispensed, days of supply, renewal interval and cancellation cutoff together. The longevity category did not return a usable product list in our check; that is a verification limitation, not evidence that all longevity treatments have been discontinued. Older prices below should be treated as dated observations until the current offer is confirmed.
Full analysis — 4 more sectionsIt names the doctor · And then the price list · What it does not claim · The products it sells and will not describe
It names the doctor
From RxSpan MD's about page:
"Meet Dr. John Diaz. Dr. John Diaz is a board-certified plastic surgeon with more than 20 years of experience… He earned his undergraduate degree from Cornell University… went on to attend the Albert Einstein College of Medicine… He received his M.D. with Distinction in Research and was honored with Alpha Omega Alpha recognition, awarded to the top 10% of medical students nationwide."
That is a real, named, checkable physician with real credentials, and most sellers we grade name nobody at all.
Read the specialty carefully, though. The board named is plastic surgery — not endocrinology, not internal medicine. That is not a disqualification: physicians prescribe lawfully outside their board specialty and many practice weight management. But a site that leads with a doctor's credentials as the reason to trust it is inviting you to look at them, so look.
And then the price list
Here is RxSpan MD's entire price list, as published:
Semaglutide Injection $249 · Semaglutide Capsules $249
Tirzepatide Injection $329 · Tirzepatide Capsules $349
Wegovy® $1,349 · Zepbound® $1069 · Ozempic® $1299
$249 for what?
A month? A three-month supply? A single vial? Look on that page for the words month, supply, per, starting and from anywhere near a figure. None of them appears.
There are no product pages to click into either — we tried three URL patterns and every one returned a not-found page. So that list is the whole of it: seven numbers with nothing attached.
A 10% coupon rides every page as well, so the first charge is below all seven, and nothing says whether it repeats.
What it does not claim
On the GLP-1 and peptide side, nothing at all. No weight-loss percentage, no pounds figure, no timeline, no testimonial. Nothing here reaches past STEP 1 1 or SURMOUNT-1 2 because nothing here reaches.
The one strong claim on the property is in a different aisle:
"Clinically proven topicals and orals to slow loss and support regrowth."
That is the hair-loss line, which this page does not grade — noted so our silence is not read as agreement.
The products it sells and will not describe
The affiliate program behind this site pays separate rates for NAD+, sermorelin and glutathione. All three appear in the price list. None has a product page, a dose, or a trial reference anywhere on the site.
They are not graded here, because grading a claim about a drug the seller has not described means inventing both halves.
Questions
Frequently asked questions
What does $249 actually buy?
RxSpan MD doesn't say. That figure sits on its products index with no billing period attached, there are no product pages to click through to, and nothing near it says month, supply or term. You would have to begin the signup to find out.
Who is the doctor?
Dr. John Diaz, named on the about page with his degree, medical school and honors. He is board-certified in plastic surgery rather than endocrinology or internal medicine, which is worth knowing on a site that presents the credential as the reason to trust it.
Does it claim how much weight I'd lose?
No — no percentage, pounds figure or timeline appears on any GLP-1 or peptide product. That means nothing here overstates the trials, and it also means the site gives you nothing to set expectations against.
Why is Wegovy five times the price?
Because it is the manufacturer's approved product rather than a compounded preparation made to order by a pharmacy. The trial evidence attaches directly to Wegovy; for the compounded version it describes the molecule rather than the preparation you would receive.
What about the NAD+ and sermorelin products?
They appear in the price list and nowhere else — no product page, no dose, no trial reference. They are not graded here, because there is nothing published to grade against.
Glossary
Key terms
Show definitions
- Board certification
- A specialty credential awarded after additional training and examination in one field of medicine. A physician may lawfully prescribe outside their board specialty; the certification tells you where their formal training was concentrated.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
Compare
Others selling what RxSpan MD sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists RxSpan MD is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off RxSpan MD's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, mean weight reduction of about 15%. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Public buyer information checked October 13, 2026. Public primary source. the RxSpan MD site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.